欧盟的CCHMP支持Pfizer-BioNTEch的Omicron改制的COVID-19疫苗,持续6个月以上。 EU's CHMP endorses Pfizer-BioNTech's Omicron-adapted COVID-19 vaccine for ages 6 months and up.

Pfizer和BioNTEch的Omicron KP.2改编的COVID-19疫苗从欧盟的CHMP获得了积极的意见,为批准6个月或6个月以上的人铺平了道路。 Pfizer and BioNTech's Omicron KP.2-adapted COVID-19 vaccine received a positive opinion from the EU's CHMP, paving the way for authorization for individuals aged 6 months and older. 这种疫苗表明,针对各种Omicron JN.1子系列,其效力有所提高。 This vaccine shows enhanced effectiveness against various Omicron JN.1 sublineages. 在欧盟批准后,剂量将根据成员国的命令分发给成员国。 Following EU approval, doses will be distributed to member states based on their orders. 在美国,为12岁及12岁以上的人批准接种疫苗,为年幼儿童发放紧急使用许可。 In the U.S., the vaccine is approved for those 12 and older, with emergency use authorization for younger children.